Agios Pharmaceuticals Q1 Earnings Call Highlights [Yahoo! Finance]
Agios Pharmaceuticals, Inc. (AGIO)
Last agios pharmaceuticals, inc. earnings: 4/30 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.agios.com/investor-overview
Company Research
Source: Yahoo! Finance
Financials: Agios reported first-quarter mitapivat net revenues of $20.7 million (U.S. $18.8M), R&D of $81M and SG&A of $48M, ended the quarter with $1 billion in cash and expects 2026 operating expenses to be roughly flat versus 2025 AQVESME U.S. launch: The REMS was fully operational by late January and Agios recorded 242 prescriptions by March 31 with early uptake among highly engaged transfusion-dependent and motivated non-transfusion-dependent patients, but management warned Q1 is not a steady run rate and expects prescription-to-initiation timelines to average ~10–12 weeks as adoption broadens. Regulatory path & pipeline catalysts: Agios plans to submit an sNDA for mitapivat in sickle cell disease in Q2 via the Accelerated Approval pathway with a confirmatory trial design underway, and expects multiple 2026 readouts including pediatric mitapivat trials, tebapivat phase II-B (MDS) top-line in H1 and tebapivat sickle cell data in H2, plus early AG-236 and AG-181 phase I resu
Show less
Read more
Impact Snapshot
Event Time:
AGIO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AGIO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AGIO alerts
High impacting Agios Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
AGIO
News
- Agios Pharmaceuticals (AGIO) had its price target lowered by Truist Financial Corporation from $39.00 to $36.00. They now have a "buy" rating on the stock.MarketBeat
- Why Agios Pharmaceuticals Stock Zoomed to a 13% Gain on Wednesday [Globe and Mail, The (Toronto, Canada)]Globe and Mail, The
- Why Agios Pharmaceuticals Stock Zoomed to a 13% Gain on Wednesday [Yahoo! Finance]Yahoo! Finance
- Agios Reports First Quarter 2026 Financial Results and Provides Business Update [Yahoo! Finance]Yahoo! Finance
- Agios Reports First Quarter 2026 Financial Results and Provides Business UpdateGlobeNewswire
AGIO
Earnings
- 4/29/26 - Beat
AGIO
Sec Filings
- 4/29/26 - Form SCHEDULE
- 4/29/26 - Form 10-Q
- 4/29/26 - Form 8-K
- AGIO's page on the SEC website